Table 2.

Prevalence of PsA and MetS among patients with plaque‐type psoriasis in a Brazilian population (n = 282)

Comorbidity	Diagnostic categories	n	%	95% CI
Psoriatic arthritis	History of PsA reported by the patient (n = 282)	65	23.1	30.1–41.3
	PsA diagnosed by the study physician, CASPAR (n = 282)	100	35.7	37.2–56.8
	Previous diagnosis among CASPAR‐positive patients (n = 100)	47	47.0	43.2–62.8
	Newly diagnosed among CASPAR‐positive patients (n = 100)	53	53.0	18.2–28.0
	Final prevalence of PsA (CASPAR or history) (n = 282)	118	41.8	36.0–47.6
Metabolic syndrome	History of MetS reported by the patient (n = 282)	17	6.0	3.2–8.8
	Diagnosis confirmed by the physician (n = 282)	137	48.6	42.8–54.4
	Patients newly diagnosed in the study (n = 141)	107	75.9	68.8–83.0
	Final prevalence of MetS (physician diagnosis or history) (n = 282)	141	50.0	44.2–55.8

CASPAR, Classification Criteria for Psoriatic Arthritis; CI, confidence interval; MetS, metabolic syndrome; PsA, psoriatic arthritis.